Matches in SemOpenAlex for { <https://semopenalex.org/work/W4302425350> ?p ?o ?g. }
- W4302425350 endingPage "101690" @default.
- W4302425350 startingPage "101690" @default.
- W4302425350 abstract "BackgroundAcute mania is a psychiatric emergency requiring rapid management. However, randomised controlled trials (RCTs) have shown considerable individual differences in treatment effects on manic symptoms with antimanic drugs.MethodsWe searched the MEDLINE, CENTRAL, EMBASE, PsycINFO, and ClinicalTrials.gov to identify RCTs without language restrictions from inception to April 19, 2022. We included double-blind RCTs of oral antimanic monotherapy versus placebo in adult patients. The primary outcome was variability in improvement of manic symptoms (assessed using the coefficient of variation ratio [CVR]). The secondary outcomes were overall improvement of manic symptoms and acceptability (i.e., discontinuation for any reason). The pooled effects of outcomes were calculated by random-effects meta-analyses using restricted maximum likelihood methods. The quality of the included studies was assessed using the Cochrane Risk of Bias (ROB) Assessment Tool. This study was registered with OSF (DOI:10.17605/OSF.IO/G4JNY).FindingsWe included 39 RCTs (N=12150; mean age=39·9 years, interquartile range [IQR]=38·7-41·1; mean proportion of female=48·6%, IQR=42·3%-52·3%) and investigated 14 antimanic drugs. We found that eight antimanic drugs compared to placebo were associated with lower CVRs (95% confidence interval [CI]; I2), including risperidone (0·51; 0·37-0·70; 0%), haloperidol (0·54; 0·44-0·67; 4%), olanzapine (0·59; 0·44-0·79; 47%), ziprasidone (0·61; 0·53-0·71; 0%), lithium (0·63; 0·52-0·76; 0%), quetiapine (0·65; 0·48-0·87; 2%), aripiprazole (0·68; 0·56-0·84; 25%), and cariprazine (0·70; 0·49-0·99; 28%). There were nine antimanic drugs associated with greater efficacy than placebo, including risperidone (reported as standardised mean difference; 95% CI; I2: 0·64; 0·31-0·97; 15%), haloperidol (0·57; 0·29-0·85; 64%), cariprazine (0·51; 0·24-0·78; 0%), olanzapine (0·44; 0·30-0·58; 0%), lithium (0·42; 0·29-0·55; 0%), ziprasidone (0·42; 0·26-0·58; 0%), quetiapine (0·40; 0·13-0·67; 0%), asenapine (0·40; 0·13-0·67; 0%), and aripiprazole (0·32; 0·14-0·49; 53%). Ziprasidone (reported as risk ratio; 95% CI; I2: 0·83; 0·79-0·89; 0%) and olanzapine (0·63; 0·49-0·80; 35%) were associated with better acceptability relative to placebo. Among the 39 RCTs, none had a high ROB.InterpretationWe demonstrated that eight antimanic drugs were associated with lower variability and better efficacy than placebo, suggesting that these antimanic drugs were associated with more homogenous and predictable improvements of manic symptoms in patients with acute mania.FundingThe study was supported by from the Ministry of Science and Technology (MOST-110-2314-B-016-035, MOST-111-2314-B-016-054), Medical Affairs Bureau (MND-MAB-D-111102), and Tri-service General Hospital (TSGH-E-111229). Acute mania is a psychiatric emergency requiring rapid management. However, randomised controlled trials (RCTs) have shown considerable individual differences in treatment effects on manic symptoms with antimanic drugs. We searched the MEDLINE, CENTRAL, EMBASE, PsycINFO, and ClinicalTrials.gov to identify RCTs without language restrictions from inception to April 19, 2022. We included double-blind RCTs of oral antimanic monotherapy versus placebo in adult patients. The primary outcome was variability in improvement of manic symptoms (assessed using the coefficient of variation ratio [CVR]). The secondary outcomes were overall improvement of manic symptoms and acceptability (i.e., discontinuation for any reason). The pooled effects of outcomes were calculated by random-effects meta-analyses using restricted maximum likelihood methods. The quality of the included studies was assessed using the Cochrane Risk of Bias (ROB) Assessment Tool. This study was registered with OSF (DOI:10.17605/OSF.IO/G4JNY). We included 39 RCTs (N=12150; mean age=39·9 years, interquartile range [IQR]=38·7-41·1; mean proportion of female=48·6%, IQR=42·3%-52·3%) and investigated 14 antimanic drugs. We found that eight antimanic drugs compared to placebo were associated with lower CVRs (95% confidence interval [CI]; I2), including risperidone (0·51; 0·37-0·70; 0%), haloperidol (0·54; 0·44-0·67; 4%), olanzapine (0·59; 0·44-0·79; 47%), ziprasidone (0·61; 0·53-0·71; 0%), lithium (0·63; 0·52-0·76; 0%), quetiapine (0·65; 0·48-0·87; 2%), aripiprazole (0·68; 0·56-0·84; 25%), and cariprazine (0·70; 0·49-0·99; 28%). There were nine antimanic drugs associated with greater efficacy than placebo, including risperidone (reported as standardised mean difference; 95% CI; I2: 0·64; 0·31-0·97; 15%), haloperidol (0·57; 0·29-0·85; 64%), cariprazine (0·51; 0·24-0·78; 0%), olanzapine (0·44; 0·30-0·58; 0%), lithium (0·42; 0·29-0·55; 0%), ziprasidone (0·42; 0·26-0·58; 0%), quetiapine (0·40; 0·13-0·67; 0%), asenapine (0·40; 0·13-0·67; 0%), and aripiprazole (0·32; 0·14-0·49; 53%). Ziprasidone (reported as risk ratio; 95% CI; I2: 0·83; 0·79-0·89; 0%) and olanzapine (0·63; 0·49-0·80; 35%) were associated with better acceptability relative to placebo. Among the 39 RCTs, none had a high ROB. We demonstrated that eight antimanic drugs were associated with lower variability and better efficacy than placebo, suggesting that these antimanic drugs were associated with more homogenous and predictable improvements of manic symptoms in patients with acute mania." @default.
- W4302425350 created "2022-10-06" @default.
- W4302425350 creator A5017280751 @default.
- W4302425350 creator A5034098370 @default.
- W4302425350 creator A5052379001 @default.
- W4302425350 creator A5056558888 @default.
- W4302425350 creator A5058630496 @default.
- W4302425350 creator A5061626486 @default.
- W4302425350 creator A5061926369 @default.
- W4302425350 creator A5067635334 @default.
- W4302425350 creator A5068719988 @default.
- W4302425350 creator A5077667312 @default.
- W4302425350 creator A5080790316 @default.
- W4302425350 creator A5083734796 @default.
- W4302425350 date "2022-12-01" @default.
- W4302425350 modified "2023-10-07" @default.
- W4302425350 title "Variability and efficacy in treatment effects on manic symptoms with lithium, anticonvulsants, and antipsychotics in acute bipolar mania: A systematic review and meta-analysis" @default.
- W4302425350 cites W1984344128 @default.
- W4302425350 cites W2003490971 @default.
- W4302425350 cites W2047066979 @default.
- W4302425350 cites W2098469032 @default.
- W4302425350 cites W2098923148 @default.
- W4302425350 cites W2128827062 @default.
- W4302425350 cites W2149988964 @default.
- W4302425350 cites W2162319254 @default.
- W4302425350 cites W2266871031 @default.
- W4302425350 cites W2588681363 @default.
- W4302425350 cites W2792027821 @default.
- W4302425350 cites W2948592229 @default.
- W4302425350 cites W2975621931 @default.
- W4302425350 cites W3007735847 @default.
- W4302425350 cites W3027892425 @default.
- W4302425350 cites W3112965713 @default.
- W4302425350 cites W3118615836 @default.
- W4302425350 cites W3131462943 @default.
- W4302425350 cites W3185053757 @default.
- W4302425350 cites W3197978990 @default.
- W4302425350 cites W3207791644 @default.
- W4302425350 cites W4210998119 @default.
- W4302425350 cites W4211013640 @default.
- W4302425350 cites W4237330839 @default.
- W4302425350 cites W4283779748 @default.
- W4302425350 cites W8807486 @default.
- W4302425350 doi "https://doi.org/10.1016/j.eclinm.2022.101690" @default.
- W4302425350 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36247926" @default.
- W4302425350 hasPublicationYear "2022" @default.
- W4302425350 type Work @default.
- W4302425350 citedByCount "1" @default.
- W4302425350 countsByYear W43024253502023 @default.
- W4302425350 crossrefType "journal-article" @default.
- W4302425350 hasAuthorship W4302425350A5017280751 @default.
- W4302425350 hasAuthorship W4302425350A5034098370 @default.
- W4302425350 hasAuthorship W4302425350A5052379001 @default.
- W4302425350 hasAuthorship W4302425350A5056558888 @default.
- W4302425350 hasAuthorship W4302425350A5058630496 @default.
- W4302425350 hasAuthorship W4302425350A5061626486 @default.
- W4302425350 hasAuthorship W4302425350A5061926369 @default.
- W4302425350 hasAuthorship W4302425350A5067635334 @default.
- W4302425350 hasAuthorship W4302425350A5068719988 @default.
- W4302425350 hasAuthorship W4302425350A5077667312 @default.
- W4302425350 hasAuthorship W4302425350A5080790316 @default.
- W4302425350 hasAuthorship W4302425350A5083734796 @default.
- W4302425350 hasBestOaLocation W43024253503 @default.
- W4302425350 hasConcept C118552586 @default.
- W4302425350 hasConcept C126322002 @default.
- W4302425350 hasConcept C142724271 @default.
- W4302425350 hasConcept C168563851 @default.
- W4302425350 hasConcept C204787440 @default.
- W4302425350 hasConcept C27081682 @default.
- W4302425350 hasConcept C2776174506 @default.
- W4302425350 hasConcept C2776412080 @default.
- W4302425350 hasConcept C2776619155 @default.
- W4302425350 hasConcept C2776809841 @default.
- W4302425350 hasConcept C2777270317 @default.
- W4302425350 hasConcept C2778541603 @default.
- W4302425350 hasConcept C2780057945 @default.
- W4302425350 hasConcept C2780634440 @default.
- W4302425350 hasConcept C2908949014 @default.
- W4302425350 hasConcept C44249647 @default.
- W4302425350 hasConcept C71924100 @default.
- W4302425350 hasConcept C95190672 @default.
- W4302425350 hasConceptScore W4302425350C118552586 @default.
- W4302425350 hasConceptScore W4302425350C126322002 @default.
- W4302425350 hasConceptScore W4302425350C142724271 @default.
- W4302425350 hasConceptScore W4302425350C168563851 @default.
- W4302425350 hasConceptScore W4302425350C204787440 @default.
- W4302425350 hasConceptScore W4302425350C27081682 @default.
- W4302425350 hasConceptScore W4302425350C2776174506 @default.
- W4302425350 hasConceptScore W4302425350C2776412080 @default.
- W4302425350 hasConceptScore W4302425350C2776619155 @default.
- W4302425350 hasConceptScore W4302425350C2776809841 @default.
- W4302425350 hasConceptScore W4302425350C2777270317 @default.
- W4302425350 hasConceptScore W4302425350C2778541603 @default.
- W4302425350 hasConceptScore W4302425350C2780057945 @default.
- W4302425350 hasConceptScore W4302425350C2780634440 @default.
- W4302425350 hasConceptScore W4302425350C2908949014 @default.
- W4302425350 hasConceptScore W4302425350C44249647 @default.
- W4302425350 hasConceptScore W4302425350C71924100 @default.